Evidence map›Paper›PMID 28465075›Full record

ArticleActa biomaterialia2017

Carbon nanotube capsules enhance the in vivo efficacy of cisplatin.

Adem Guven, Gabriel J Villares, Susan G Hilsenbeck, Alaina Lewis, John D Landua, Lacey E Dobrolecki, Lon J Wilson, Michael T Lewis

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biomaterialia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Application of nanoparticles in breast cancer treatment: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Adem GuvenDepartment of Chemistry and the Smalley-Curly Institute, MS-60, P.O. Box 1892, Rice University, Houston, TX 77251-1892, USA.
Gabriel J VillaresDepartments of Molecular and Cellular Biology and Radiology, Lester and Sue Smith Breast Center at Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA; Department of Biology, University of St. Thomas, 3800 Montrose Boulevard, Houston, TX 77006, USA.
Susan G HilsenbeckDan L. Duncan Cancer Center Division of Biostatistics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Alaina LewisDepartments of Molecular and Cellular Biology and Radiology, Lester and Sue Smith Breast Center at Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
John D LanduaDepartments of Molecular and Cellular Biology and Radiology, Lester and Sue Smith Breast Center at Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Lacey E DobroleckiDepartments of Molecular and Cellular Biology and Radiology, Lester and Sue Smith Breast Center at Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Lon J WilsonDepartment of Chemistry and the Smalley-Curly Institute, MS-60, P.O. Box 1892, Rice University, Houston, TX 77251-1892, USA. Electronic address: durango@rice.edu.
Michael T LewisDepartments of Molecular and Cellular Biology and Radiology, Lester and Sue Smith Breast Center at Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA. Electronic address: mtlewis@bcm.edu.
Baylor College of Medicine · USRice University · USUniversity of St. Thomas - Texas · US

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9M
TUMOR SUPPRESSOR GENES IN BREAST CANCER DEVELOPMENTP50CA058183 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI OSBORNE, C KENT · 1992 to 2012
$30.9M
The Core of the Computational BiologyU54CA149196 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI WONG, STEPHEN TC · 2010 to 2015
$10.6M
Research Education and Career Horizons ProgramK12GM084897 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI SIFERS, RICHARD NORMAN, SLAUGHTER, GAYLE · 2008 to 2016
$8.3M
Regulation of Mammary Stem CellsR01CA127857 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LEWIS, MICHAEL T. · 2008 to 2012
$1.7M
NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA058183NCI NIH HHS R01 CA127857NCI NIH HHS U54 CA149196NIGMS NIH HHS K12 GM084897
6 · The paper itself

Abstract

Over the past few years, numerous nanotechnology-based drug delivery systems have been developed in an effort to maximize therapeutic effectiveness of conventional drug delivery, while limiting undesirable side effects. Among these, carbon nanotubes (CNTs) are of special interest as potential drug delivery agents due to their numerous unique and advantageous physical and chemical properties. Here, we show in vivo favorable biodistribution and enhanced therapeutic efficacy of cisplatin (CDDP) encapsulated within ultra-short single-walled carbon nanotube capsules (CDDP@US-tubes) using three different human breast cancer xenograft models. In general, the CDDP@US-tubes demonstrated greater efficacy in suppressing tumor growth than free CDDP in both MCF-7 cell line xenograft and BCM-4272 patient-derived xenograft (PDX) models. The CDDP@US-tubes also demonstrated a prolonged circulation time compared to free CDDP which enhanced permeability and retention (EPR) effects resulting in significantly more CDDP accumulation in tumors, as determined by platinum (Pt) analysis via inductively-coupled plasma mass spectrometry (ICP-MS). STATEMENT OF SIGNIFICANCE: Over the past decade, drug-loaded nanocarriers have been widely fabricated and studied to enhance tumor specific delivery. Among the diverse classes of nanomaterials, carbon nanotubes (CNTs), or more specifically ultra-short single-walled carbon nanocapsules (US-tubes), have been shown to be a popular, new platform for the delivery of various medical agents for both imaging and therapeutic purposes. Here, for the first time, we have shown that US-tubes can be utilized as a drug delivery platform in vivo to deliver the chemotherapeutic drug, cisplatin (CDDP) as CDDP@US-tubes. The studies have demonstrated the ability of the US-tube platform to promote the delivery of encapsulated CDDP by increasing the accumulation of drug in breast cancer resistance cells, which reveals how CDDP@US-tubes help overcome CDDP resistance.

Indexed as

Antineoplastic AgentsCisplatinNanocapsulesAnimalsHumansMCF-7 CellsMiceNanotubes, CarbonNeoplasms, ExperimentalXenograft Model Antitumor AssaysAntineoplastic AgentsCisplatinNanocapsulesNanotubes, CarbonBreast cancerCisplatinDrug deliveryNanotechnologySingle-walled carbon nanotube

Identifiers

PMID28465075
PMCPMC6344128
OpenAlexW2610532047

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.